SUMMARY Penicillamine has been successfully reintroduced and continued for a minimum of 13 months in 5 patients who developed proteinuria during the first course of the drug. The daily maintenance dose during the second course was 150-250 mg taken midway between 2 meals. Proteinuria did not recur; no significant excretion of fibrin degradation products occurred; complement, urea, creatinine, and serum albumin remained within normal limits. Urine microscopy showed no abnormality.
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Proteinuria is a major reason for abandoning treatment with penicillamine in patients with rheumatoid arthritis. In a personal series (Hill, 1977) 16 of 69 patients (23%) treated with a daily maintenance dose of 750 mg developed proteinuria exceeding 2 g/24 hours during the first 12 months of treatment and penicillamine was consequently withdrawn. In most of these 16 patients the disease subsequently became only slightly more active, but in a few deterioration was so severe that the patients and their families pressed strongly for resumption of treatment. Jaffe (1977-8) reported that reintroduction of penicillamine, starting with a daily dose of 250 mg, was usually followed by a return of proteinuria at about the same time and at about the same cumulative dose as on the first occasion. The object of this study was to determine whether cautious reintroduction of penicillamine could be accomplished without a return of proteinuria, and whether the use of very much smaller doses would be clinically effective.
Materials and methods

ADMISSION CRITERIA
The reintroduction of penicillamine was considered only for patients who had had a good clinical and laboratory response to the drug during the first course, whose disease was again persistently active, and who requested a further trial of penicillamine. Further conditions of entry were that the urine had become free from protein after penicillamine was withdrawn and had remained so for at least 3 months; serum urea, creatinine, and albumin had to be within normal limits; and no red cells or casts were present on urine microscopy. Five patients fulfilled these criteria. Four of these were normotensive, the fifth had hypertension which antedated the first use of penicillamine and had not subsequently increased. There was thus no evidence of nephropathy in these 5 patients. The salient features of the first course of treatment are summarised in Table 1 .
DOSE
The initial dose of penicillamine was 50 mg, increased by monthly increments of 50 mg to a maintenance dose of 150 mg daily. The dose was held at 150 mg/day for 4 months and thereafter increased by further increments of 50 mg at intervals of 3 months if the disease remained persistently active. In an attempt to standardise treatment and to ensure maximum absorption of the 50 mg tablets patients were instructed to take their daily dose of penicillamine midway between 2 meals, so that at least 1 hours elapsed after the end of one meal before penicillamine was taken and at least a further Ij hours elapsed before the next meal. During this 3-hour period only water was allowed. Initially penicillamine was given in 2 divided doses, but patients who had completed 6 months of treatment were given the option of taking the drug in a single dose at a time best suited to their individual convenience. Some of these patients who woke early opted for early morning as the most convenient time, postponing breakfast if necessary. (Clarkson et al., 1970) . Clinical assessment of disease activity was based on the duration of morning stiffness, examination of affected joints, and counting the number of joints which were free from pain on a full range of nonweight bearing active movement (Hill et al., 1973 Table 2 .
Comparison between the effect of a maintenance dose of 750 or 1500 mg of penicillamine in the first course and 150-250 mg in the second can be made only in respect of ESR and CRP as the number of pain-free joints, and the duration of morning stiffness was not recorded regularly during the first course. Nevertheless, comparable changes in ESR and CRP during both courses suggest that the comparatively small dose of penicillamine used in the second course did reduce disease activity.
Four of the 5 patients continue with penicillamine, the maximum duration of treatment amounting to 24 months. Penicillamine was withdrawn in the fifth patient after 13 months when she developed widespread pruritic skin lesions characteristic of Resumption of treatment with penicillamine after proteinuria 231 pemphigus foliaceus-another adverse effect of penicillamine (Marsden et al., 1976) . In retrospect the 2 tiny blisters which accompanied the development of proteinuria during the first course of treatment in this patient were probably early lesions of pemphigus foliaceous; the lack of pruritus and the brief duration of the rash which occurred at that time may have been due to the prompt withdrawal of penicillamine.
Discussion
The object of this study was to see if penicillamine could be reintroduced without inducing proteinuria if a very low dose were used. This object has been achieved, all patients completing a minimum of 13 months of treatment, the urine remaining free from protein throughout. Proteinuria at 'normal' doses of 750 mg or more of penicillamine occurs most often during the second 6 months of treatment. All 5 patients have passed this high risk time without recurrence of proteinuria. Proteinuria, though rare after 12 months of treatment (Hill, 1977) , may occur at wide ranges of dose and length of treatment (Davison et al., 1977) . Urinary FDP excretion correlates with intraglomerular fibrin deposition (Davison et al., 1973) and this relates to the severity of the glomerular inflammation and may be a more sensitive indicator of glomerular disease. The lack of any significant urinary FDP excretion during this study therefore indirectly indicates the lack of any penicillamine-induced nephropathy. Jaffe (1977-8) found that proteinuria occurred at the same time and after the same cumulative dose if penicillamine was reintroduced at higher dose levels. In contrast, in the small group of patients in the present study reintroduction of penicillamine in a very small dose was not followed by recurrence of proteinuria, and all have now passed the time in treatment at which proteinuria occurred in the original course. However, the results do not run counter to those of Jaffe in respect of recurrence of proteinuria at the same cumulative dose level as in the first course, since none of our patients has yet had a total dose of penicillamine in the second course approaching that reached in the first course when proteinuria appeared. Even the patient who has been taking 200 mg/day for a total of 24 months has so far reached only just over half the total dose of penicillamine which she took during the first course. Clearly the study must continue until the 'critical' cumulative dose has been reached and passed.
The decision to specify that the drug be taken between meals and with water only was prompted by the observation of Lyle et al. (1977) 
